Literature DB >> 10496193

Familial dilated cardiomyopathy: echocardiographic diagnostic criteria for classification of family members as affected.

R E Hershberger1, H Ni, K A Crispell.   

Abstract

BACKGROUND: Echocardiographic criteria for left ventricular enlargement (LVE) used to classify subjects as affected in families with familial dilated cardiomyopathy (FDC) have been inconsistent. A recent report from a large Framingham echocardiographic study provides an opportunity to improve the assignment of LVE and FDC in kindreds, principally with a dilated phenotype. The objective of this study is to evaluate an alternative diagnostic criteria for FDC based only on LVE with no measure of fractional shortening (FS). METHODS AND
RESULTS: We compared our proposed criteria for LVE and FDC with previous approaches by applying them to 166 adults derived from three large FDC pedigrees. Our proposed FDC diagnostic criteria are a sex- and height-specific method based only on LVE, without regard for FS, set as a 97.5% upper limit for left ventricular end-diastolic dimension (LVEDD) from the Framingham study. Other methods used to assign LVE were (1) a 95% upper limit for LVEDD by the Framingham study; (2) the method of Henry et al. (1980) based on age and body surface area (BSA); and (3) the National Heart, Lung, and Blood Institute (NHLBI) method with a cut point of LVEDD greater than 2.7 cm/BSA. Three other commonly used diagnostic criteria for FDC were based on various LVE standards combined with an FS of 27% to 30%. For LVE, the Framingham-97.5% was the most stringent (21 of 134 subjects identified; 15.7%), the NHLBI standard the least stringent (57 of 161 subjects identified; 35.4%), and the Henry-112% method intermediate (44 of 161 subjects identified; 27.3%). More women were identified with the Framingham method (57.1%) versus the Henry-112% (40.9%). The Henry-112% and NHLBI methods identified 11.4% and 7.0% of subjects with body mass indices (BMIs) of 35 or greater, respectively. For FDC, our proposed FDC diagnostic criteria identified similar numbers of subjects (21 subjects) as the three other criteria (range, 22 to 27 subjects), but inconsistency was noted (54.2% to 66.7%), with kappa values from 0.49 to 0.55 resulting from different sensitivities to sex, LVE, FS, and BMI.
CONCLUSION: Our proposed FDC diagnostic criteria are stringent to assign FDC family members as affected compared with other commonly used criteria. The use of LVEDD alone may be preferable for FDC family screening, although further validation of this approach with phenotypic and genotypic data from other large FDC pedigrees is needed.

Entities:  

Mesh:

Year:  1999        PMID: 10496193     DOI: 10.1016/s1071-9164(99)90005-2

Source DB:  PubMed          Journal:  J Card Fail        ISSN: 1071-9164            Impact factor:   5.712


  4 in total

1.  Genetic Counseling and Screening Issues in Familial Dilated Cardiomyopathy.

Authors:  E L Hanson; R E Hershberger
Journal:  J Genet Couns       Date:  2001-10       Impact factor: 2.537

2.  Left ventricular volume: an optimal parameter to detect systolic dysfunction on prospectively triggered 64-multidetector row computed tomography: another step towards reducing radiation exposure.

Authors:  Mohit Gupta; Yalcin Hacioglu; Jigar Kadakia; Naser Ahmadi; Yanlin Gao; Song S Mao; Matthew J Budoff
Journal:  Int J Cardiovasc Imaging       Date:  2010-11-10       Impact factor: 2.357

3.  Cardiac magnetic resonance imaging of myocardial contrast uptake and blood flow in patients affected with idiopathic or familial dilated cardiomyopathy.

Authors:  Michael Jerosch-Herold; David C Sheridan; Jessica D Kushner; Deirdre Nauman; Donna Burgess; Diana Dutton; Rami Alharethi; Duanxiang Li; Ray E Hershberger
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-07-25       Impact factor: 4.733

4.  Clinical and genetic issues in dilated cardiomyopathy: a review for genetics professionals.

Authors:  Ray E Hershberger; Ana Morales; Jill D Siegfried
Journal:  Genet Med       Date:  2010-11       Impact factor: 8.822

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.